Pre-Vaccination Human Papillomavirus Genotypes and HPV16 Variants among Women Aged 25 Years or Less with Cervical Cancer
Background: In 2007, Australia introduced a national human papillomavirus (HPV) vaccination program. In 2017, the onset of cervical screening changed from 18 to 25 years of age, utilising human papillomavirus (HPV) nucleic acid testing. The objective of the study is to describe the HPV genotypes and...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Pathogens |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-0817/12/3/451 |
| _version_ | 1797609674074226688 |
|---|---|
| author | Yasmin L. Jayasinghe Sepehr N. Tabrizi Matthew Stevens Trishe Y-M. Leong Jan Pyman Sonia R. Grover Suzanne M. Garland the Early-Onset Cervical Cancer (EOCC) Study Group |
| author_facet | Yasmin L. Jayasinghe Sepehr N. Tabrizi Matthew Stevens Trishe Y-M. Leong Jan Pyman Sonia R. Grover Suzanne M. Garland the Early-Onset Cervical Cancer (EOCC) Study Group |
| author_sort | Yasmin L. Jayasinghe |
| collection | DOAJ |
| description | Background: In 2007, Australia introduced a national human papillomavirus (HPV) vaccination program. In 2017, the onset of cervical screening changed from 18 to 25 years of age, utilising human papillomavirus (HPV) nucleic acid testing. The objective of the study is to describe the HPV genotypes and HPV16 variants in biopsies from women ≤ 25 years of age with cervical carcinoma (CC) (cases), compared with those aged >25 years (controls), in a pre-vaccination cohort. Methods: HPV genotyping of archival paraffin blocks (<i>n</i> = 96) was performed using the INNO-LiPA HPV Genotyping assay. HPV16-positive samples were analysed for variants by type-specific PCR spanning L1, E2 and E6 regions. Results: HPV16 was the commonest genotype in cases (54.5%, 12/22) and controls (66.7%, 46/69) (<i>p</i> = 0.30), followed by HPV18 (36.3%, 8/22 vs. 17.3% 12/69, respectively) (<i>p</i> = 0.08). Furthermore, 90% (20/22) of cases and 84.1% (58/69) of controls were positive for HPV16 or 18 (<i>p</i> = 0.42); 100% (22/22) of cases and 95.7% (66/69) of controls had at least one genotype targeted by the nonavalent vaccine (<i>p</i> = 0.3). The majority of HPV16 variants (87.3%, 48/55) were of European lineage. The proportion of unique nucleotide substitutions was significantly higher in cases (83.3%, 10/12) compared with controls (34.1%, 15/44), (<i>p</i> < 0.003, χ<sup>2</sup>, OR 9.7, 95%CI 1.7–97.7). Conclusions: Virological factors may account for the differences in CCs observed in younger compared with older women. All CCs in young women in this study had preventable 9vHPV types, which is important messaging for health provider adherence to new cervical screening guidelines. |
| first_indexed | 2024-03-11T06:03:41Z |
| format | Article |
| id | doaj.art-e730ab2bea53439f8e77d1a06f1e5833 |
| institution | Directory Open Access Journal |
| issn | 2076-0817 |
| language | English |
| last_indexed | 2024-03-11T06:03:41Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pathogens |
| spelling | doaj.art-e730ab2bea53439f8e77d1a06f1e58332023-11-17T13:10:09ZengMDPI AGPathogens2076-08172023-03-0112345110.3390/pathogens12030451Pre-Vaccination Human Papillomavirus Genotypes and HPV16 Variants among Women Aged 25 Years or Less with Cervical CancerYasmin L. Jayasinghe0Sepehr N. Tabrizi1Matthew Stevens2Trishe Y-M. Leong3Jan Pyman4Sonia R. Grover5Suzanne M. Garland6the Early-Onset Cervical Cancer (EOCC) Study GroupDepartment of Obstetrics and Gynaecology, Royal Women’s Hospital, The University of Melbourne, Melbourne, VIC 3010, AustraliaDepartment of Obstetrics and Gynaecology, Royal Women’s Hospital, The University of Melbourne, Melbourne, VIC 3010, AustraliaThe Australian Genome Research Facility, Melbourne, VIC 3050, AustraliaDepartment of Anatomical Pathology, St. Vincents Hospital, Melbourne, VIC 3000, AustraliaDepartment of Anatomical Pathology, Royal Women’s Hospital, Melbourne, VIC 3010, AustraliaDepartment of Gynaecology, Royal Children’s Hospital, Melbourne, VIC 3010, AustraliaDepartment of Obstetrics and Gynaecology, Royal Women’s Hospital, The University of Melbourne, Melbourne, VIC 3010, AustraliaBackground: In 2007, Australia introduced a national human papillomavirus (HPV) vaccination program. In 2017, the onset of cervical screening changed from 18 to 25 years of age, utilising human papillomavirus (HPV) nucleic acid testing. The objective of the study is to describe the HPV genotypes and HPV16 variants in biopsies from women ≤ 25 years of age with cervical carcinoma (CC) (cases), compared with those aged >25 years (controls), in a pre-vaccination cohort. Methods: HPV genotyping of archival paraffin blocks (<i>n</i> = 96) was performed using the INNO-LiPA HPV Genotyping assay. HPV16-positive samples were analysed for variants by type-specific PCR spanning L1, E2 and E6 regions. Results: HPV16 was the commonest genotype in cases (54.5%, 12/22) and controls (66.7%, 46/69) (<i>p</i> = 0.30), followed by HPV18 (36.3%, 8/22 vs. 17.3% 12/69, respectively) (<i>p</i> = 0.08). Furthermore, 90% (20/22) of cases and 84.1% (58/69) of controls were positive for HPV16 or 18 (<i>p</i> = 0.42); 100% (22/22) of cases and 95.7% (66/69) of controls had at least one genotype targeted by the nonavalent vaccine (<i>p</i> = 0.3). The majority of HPV16 variants (87.3%, 48/55) were of European lineage. The proportion of unique nucleotide substitutions was significantly higher in cases (83.3%, 10/12) compared with controls (34.1%, 15/44), (<i>p</i> < 0.003, χ<sup>2</sup>, OR 9.7, 95%CI 1.7–97.7). Conclusions: Virological factors may account for the differences in CCs observed in younger compared with older women. All CCs in young women in this study had preventable 9vHPV types, which is important messaging for health provider adherence to new cervical screening guidelines.https://www.mdpi.com/2076-0817/12/3/451cervical canceryoung womenhuman papillomavirusgenotypingHPV vaccineHPV16 variants |
| spellingShingle | Yasmin L. Jayasinghe Sepehr N. Tabrizi Matthew Stevens Trishe Y-M. Leong Jan Pyman Sonia R. Grover Suzanne M. Garland the Early-Onset Cervical Cancer (EOCC) Study Group Pre-Vaccination Human Papillomavirus Genotypes and HPV16 Variants among Women Aged 25 Years or Less with Cervical Cancer Pathogens cervical cancer young women human papillomavirus genotyping HPV vaccine HPV16 variants |
| title | Pre-Vaccination Human Papillomavirus Genotypes and HPV16 Variants among Women Aged 25 Years or Less with Cervical Cancer |
| title_full | Pre-Vaccination Human Papillomavirus Genotypes and HPV16 Variants among Women Aged 25 Years or Less with Cervical Cancer |
| title_fullStr | Pre-Vaccination Human Papillomavirus Genotypes and HPV16 Variants among Women Aged 25 Years or Less with Cervical Cancer |
| title_full_unstemmed | Pre-Vaccination Human Papillomavirus Genotypes and HPV16 Variants among Women Aged 25 Years or Less with Cervical Cancer |
| title_short | Pre-Vaccination Human Papillomavirus Genotypes and HPV16 Variants among Women Aged 25 Years or Less with Cervical Cancer |
| title_sort | pre vaccination human papillomavirus genotypes and hpv16 variants among women aged 25 years or less with cervical cancer |
| topic | cervical cancer young women human papillomavirus genotyping HPV vaccine HPV16 variants |
| url | https://www.mdpi.com/2076-0817/12/3/451 |
| work_keys_str_mv | AT yasminljayasinghe prevaccinationhumanpapillomavirusgenotypesandhpv16variantsamongwomenaged25yearsorlesswithcervicalcancer AT sepehrntabrizi prevaccinationhumanpapillomavirusgenotypesandhpv16variantsamongwomenaged25yearsorlesswithcervicalcancer AT matthewstevens prevaccinationhumanpapillomavirusgenotypesandhpv16variantsamongwomenaged25yearsorlesswithcervicalcancer AT trisheymleong prevaccinationhumanpapillomavirusgenotypesandhpv16variantsamongwomenaged25yearsorlesswithcervicalcancer AT janpyman prevaccinationhumanpapillomavirusgenotypesandhpv16variantsamongwomenaged25yearsorlesswithcervicalcancer AT soniargrover prevaccinationhumanpapillomavirusgenotypesandhpv16variantsamongwomenaged25yearsorlesswithcervicalcancer AT suzannemgarland prevaccinationhumanpapillomavirusgenotypesandhpv16variantsamongwomenaged25yearsorlesswithcervicalcancer AT theearlyonsetcervicalcancereoccstudygroup prevaccinationhumanpapillomavirusgenotypesandhpv16variantsamongwomenaged25yearsorlesswithcervicalcancer |